Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs), and also is inviting participation in a prize competition. Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.


FOAs with EGRP Staff as Scientific Contacts

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-17-444External Web Site Policy (R01)
PA-17-446External Web Site Policy (R21)
PA-17-445External Web Site Policy (R03)
Standard dates applyExternal Web Site Policy Sept. 8, 2020

Summary:
These Funding Opportunity Announcements (FOAs) invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Proposed approaches for R01 applications may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.Of particular interest for R21 applications are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. For R03 applications, projects of particular interest are those that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. The R03 mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. For more information: PA-17-444External Web Site Policy (R01), PA-17-446External Web Site Policy (R21), and PA-17-445External Web Site Policy (R03).

Contact: Charlisse Caga-anan, J.D., Program Director, Genomic Epidemiology Branch, e-mail: charlisse.caga-anan@nih.gov

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research
Summary Details
PAR-17-279External Web Site Policy (R01)
PA-17-278External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy May 8, 2020

Summary:
This FOA invites applications proposing clinical research to identify and better understand the unique challenges to achieve a functional cure in HIV/HBV+ co-infected hosts as well as advance the discovery and development of novel strategies to achieve HBV functional cure for HIV/HBV+ co-infected adult and pediatric populations, including children, adolescents and HIV exposed uninfected children. Although clinical trials and establishment of new cohorts will not be supported by this FOA, the leveraging of ongoing NIH- or non-NIH supported clinical trials and cohorts to collect samples and data to address areas of research interests is encouraged. For more information: PAR-17-279External Web Site Policy (R01) and PA-17-278External Web Site Policy (R21).

Contact: Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts
Summary Details
PAR-17-233External Web Site Policy (U01) Standard dates applyExternal Web Site Policy May 8, 2020

Summary:
Through this FOA, NCI encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities. For more information: PAR-17-223External Web Site Policy (U01) and FAQs

Contact: Joanne Elena, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: elenajw@mail.nih.gov

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes
Summary Details
PA-17-239External Web Site Policy (R01)
PA-17-243External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy May 8, 2020

Summary:
This FOA encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data. Applications to this FOA are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. For more information: PA-17-239External Web Site Policy (R01) and PA-17-243External Web Site Policy (R21)

Contact: Melissa Rotunno, Ph.D., Program Director, Genomic Epidemiology Branch, e-mail: rotunnom@mail.nih.gov

Genomic Community Resources
Summary Details
PAR-17-273External Web Site Policy (U24) Standard dates applyExternal Web Site Policy Jan. 26, 2020

Summary:
Awards under this FOA will support the development and distribution of genomic resources that will be valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples). NCI is interested in any of the above types of resources that focus on cancer. For more information: PAR-17-273External Web Site Policy (U24).

Contact: Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch. e-mail: mechanil@mail.nih.gov

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations
Summary Details
PA-17-041External Web Site Policy (R01)
PA-17-042External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy Jan. 8, 2020

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations. For more information: PA-17-041External Web Site Policy (R01) and PA-17-042External Web Site Policy (R21).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: martinda@mail.nih.gov; and Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch, e-mail: lamt@mail.nih.gov

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
Summary Details
PA-17-060External Web Site Policy (R01)
PA-17-061External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy Jan. 8, 2020

Summary:
The purpose of this FOA is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on specific cancer type; class of drugs; and/or groups subject to disparities. Research may be focused at the patient, patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. EGRP is partnering with other Programs in the Division of Cancer Control and Population Sciences (DCCPS) to sponsor this FOA. For more information: PA-17-060External Web Site Policy (R01) and PA-17-061External Web Site Policy (R21).

Contact: Kelly K. Filipski, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: filipskikk@mail.nih.gov

Clinical and Epidemiological Research on Chronic Disease in the Caribbean
Summary Details
PAR-17-470External Web Site Policy (R01) Nov. 15, 2017
Nov. 15, 2018
Nov. 15, 2019
Nov. 16, 2019

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support U.S.-Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region that are aligned with existing publicly available U.S. datasets. The intent is for these cohorts or datasets to be used for ongoing comparative research to better understand the health of Caribbean immigrant populations in the U.S. For more information: PAR-17-470External Web Site Policy (R01).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: martinda@mail.nih.gov

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers
Summary Details
PA-16-426External Web Site Policy (R01)
PA-16-425External Web Site Policy (R21)
Standard AIDS dates applyExternal Web Site Policy Sept. 8, 2019

Summary:
The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. For more information: PA-16-426External Web Site Policy (R01) and PA-16-425External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Secondary Analyses of Alcohol and Chronic Disease
Summary Details
PA-16-395External Web Site Policy (R01)
PA-16-394External Web Site Policy (R03)
Standard dates applyExternal Web Site Policy Sept. 8, 2019

Summary:
This FOA encourages use of existing datasets to examine associations between alcohol and non-communicable chronic diseases. A population of particular interest is older adults, however, other populations that are understudied may be considered, including but not limited to pregnant women, pre-and post-menopausal women, cancer survivors, and other populations defined by stage-of-life and race/ethnicity. Factors of interest that may interact with alcohol include, but are not limited to, concurrent use of prescription or illicit drugs, lifestyle factors such as smoking, diet, and physical activity, and genetics including gene-environment interactions. Alcohol may be considered in numerous ways, including, but not limited to, average volume, quantity/frequency, binge, drinking with meals, lifetime drinking, and presence of alcohol use disorders. Studies examining both the benefits and harms of drinking are of interest as well as studies of moderate and heavy drinking. Sources of data may include, but are not limited to previously conducted epidemiologic studies (cross-sectional or cohort) and clinical trials. For more information: PA-16-395External Web Site Policy (R01) and PA-16-394External Web Site Policy (R03).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Exploratory Grants in Cancer Epidemiology and Genomics Research
Summary Details
PA-16-175External Web Site Policy (R21) Standard dates applyExternal Web Site Policy May 8, 2019

Summary:
This FOA invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. For more information: PA-16-175External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Obesity Policy Evaluation Research
Summary Details
PA-16-165External Web Site Policy (R01) Standard dates applyExternal Web Site Policy May 8, 2019

Summary:
This FOA encourages applications that propose to evaluate large scale policy or programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. For more information: PA-16-165External Web Site Policy (R01).

Contact: Jill Reedy, Ph.D., M.P.H., R.D., Program Director, Risk Factor Assessment Branch, e-mail: reedyj@mail.nih.gov

Mechanisms of Disparities in Chronic Liver Diseases and Cancer
Summary Details
PAR-17-151External Web Site Policy (R01)
PAR-17-150External Web Site Policy (R21)
Apr. 4, 2018
Apr. 4, 2019
Apr. 5, 2019

Summary:
This FOA invites applications that include multidisciplinary research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and hepatocellular carcinoma (HCC). In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA. Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate. For more information: PAR-17-151External Web Site Policy (R01) and PAR-17-150External Web Site Policy (R21).

Contact: Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: lamt@nih.gov

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Summary Details
PA-16-035External Web Site Policy (R01)
PA-16-036External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy Jan. 8, 2019

Summary:
This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE). For more information: PA-16-035External Web Site Policy (R01) and PA-16-036External Web Site Policy (R21).

Contact: Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch; e-mail: nonniekaye.shelburne@nih.gov

Social Epigenomics Research Focused on Minority Health and Health Disparities
Summary Details
PAR-16-355External Web Site Policy (R01) Nov. 15, 2017
Nov. 15, 2018
Nov. 16, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations. For more information: PAR-16-355External Web Site Policy (R01).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Time-Sensitive Obesity Policy and Program Evaluation
Summary Details
PAR-15-346External Web Site Policy (R01) Aug. 10, Sept. 11, Oct. 10, Nov. 13, and Dec. 11, 2017
Jan. 1, Feb. 13, Mar. 13, Apr. 10, May 10, June 11, July 10, Aug. 10, and Sept. 13, 2018
Sept. 14, 2018

Summary:
This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. For more information: PAR-15-346External Web Site Policy (R01).

Contact: Jill Reedy, Ph.D., M.P.H., R.D., Program Director, Risk Factor Assessment Branch, e-mail: reedyj@mail.nih.gov

Diet and Physical Activity Assessment Methodology
Summary Details
PA-16-167External Web Site Policy (R01)
PAR-15-171External Web Site Policy (R21)

R01: Standard dates applyExternal Web Site Policy.

New R21 applications: Oct. 16, 2017; and June 16, 2018 (alternating standard due dates)

R21 resubmission applications: Nov. 16, 2017; and July 16, 2018 (alternating standard due dates)

May 8, 2019 (R01)
Sept. 8, 2018 (R21)

Summary:
These FOAs encourage innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under these FOAs are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. Several other NIH Institutes are also cosponsors of these FOAs. For more information: PA-16-167External Web Site Policy (R01) and PAR-15-171External Web Site Policy (R21).

For diet assessment questions: Amy Subar, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: subara@mail.nih.gov

For physical activity assessment questions: Richard Troiano, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: troianor@mail.nih.gov

Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention
Summary Details
PAR-15-308External Web Site Policy (R01)
PAR-15-309External Web Site Policy (R21)
Nov. 21, 2017
July 11, 2018
July 12, 2018

Summary:
These FOAs, co-sponsored by NCI and the National Institute of Environmental Health Sciences (NIEHS) encourage research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. For more information: PAR-15-308External Web Site Policy (R01) and PAR-15-309External Web Site Policy (R21).

Contact: Gabriel Lai, Ph.D., Program Director, Environmental Epidemiology Branch; e-mail: laigy@mail.nih.gov

Translational Research on Adducts in Cancer Risk Identification and Prevention
Summary Details
PAR-15-307External Web Site Policy (U01) Nov. 21, 2017
July 11, 2018
July 12, 2018

Summary:
This FOA, co-sponsored by NCI and the National Institute of Environmental Health Sciences (NIEHS), encourages clinically-relevant translational/epidemiological research projects focused on the use of adducts to cellular macromolecules, as indicators of exposures to cancer risk factors in human populations and subgroups. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The projects are expected to be based on comprehensive use of human biospecimens for which detailed medical data are available (e.g., biospecimens from the NCI-supported cohort studies). The main emphasis of this FOA is on advancing the area of cancer detection, cancer prevention, and assessing cancer risks in human populations and subgroups. For more information: PAR-15-307External Web Site Policy (U01).

Contact: Gabriel Lai, Ph.D., Program Director, Environmental Epidemiology Branch; e-mail: laigy@mail.nih.gov

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes
Summary Details
RFA-CA-17-041External Web Site Policy (U01) Letter of intent due Dec. 9, 2017
Applications due Jan. 9, 2018
Jan. 10, 2018

Summary:
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot InitiativeExternal Web Site Policy that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E [PDF]External Web Site Policy: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This FOA invites U01 application for projects aimed at identifying best practices to improve case ascertainment of hereditary cancers, with the goal of improving prevention and detection. For more information: RFA-CA-17-041External Web Site Policy (U01).

Contact: Nonniekaye Shelburne, M.S., C.R.N.P., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch, e-mail: nshelburne@mail.nih.gov

Early-life Factors and Cancer Development Later in Life
Summary Details
PA-15-124External Web Site Policy (R03)
PA-15-125External Web Site Policy (R21)
PA-15-126External Web Site Policy (R01)
Standard dates applyExternal Web Site Policy Jan. 8, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. In particular, this FOA supports research efforts that will help illuminate 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies. For more information: PA-15-124External Web Site Policy (R03), PA-15-125External Web Site Policy (R21), and PA-15-126External Web Site Policy (R01).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Turkey-US Collaborative Program for Affordable Medical Technologies
Summary Details
PAR-15-276External Web Site Policy (R01) Standard dates applyExternal Web Site Policy Jan. 8, 2018

Summary:
This FOA invites applications from research partnerships formed between U.S. and Turkish scientists to aid the development of appropriate affordable diagnostic and therapeutic technologies to address medical needs in low-middle resource settings. Appropriate medical technologies are those that are useable, cost effective, sustainable, and effective in meeting a significant clinical need in a lower-middle resource setting in different world regions. The FOA encourages efforts towards developing or reengineering existing medical technologies to make them affordable and efficient so that they will have a significant impact on cancer. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is a cosponsor of this FOA. For more information: PA-14-276External Web Site Policy (R01).

Contact: Rao L. Divi, Ph.D., Program Director, Methods and Technologies Branch, e-mail: divir@mail.nih.gov

Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research
Summary Details
PAR-16-052External Web Site Policy (R21) Dec. 14, 2017 Dec. 15, 2017

Summary:
This Funding Opportunity Announcement (FOA) supports planning, design and initial pilots for locally relevant and catalytic research on non-communicable diseases (NCDs) or injury in low and middle-income countries (LMICs). Research addressing multiple NCDs and their risk factors and research addressing NCDs as comorbidities for/with infectious diseases including HIV/AIDS is encouraged. Scientists in the United States (U.S.) or upper middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions.Pilot activities and research are expected to inform the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address NCDs and injury throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. For applications on any research topic related to the brain, nervous system, mental health and substance abuse please see the companion FOA: PAR-14-331External Web Site Policy (R21). For more information: PAR-16-052External Web Site Policy (R21).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, email: martinda@mail.nih.gov

Expanding Genome Integrity Assays to Population Studies
Summary Details
RFA-ES-17-006External Web Site Policy (U01) Oct. 13, 2017 Oct. 14, 2017

Summary:
This FOA is designed to enable development and pilot testing of assays that will facilitate the wider use of genome integrity investigation into epidemiological and population studies. Epidemiological, clinical, or population investigations involving human subjects focused on associations between environmental stressors and the risk of environmentally influenced disorders should be integrated with supporting studies of assay development. For more information: RFA-ES-17-006External Web Site Policy (U01).

Contact: Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: mechanil@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP



Stay Up to Date

Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations.

Return to Top